These Companies Help Parents Try to Pick Their Babies' Traits. Experts Are Wary

Why It Matters

Polygenic embryo screening could reshape reproductive decision‑making and spark regulatory battles, while raising profound ethical questions about designer babies.

Key Takeaways

• Herasight and Nucleus Genomics sell polygenic scores for disease and traits
• Scores claim to predict height, BMI, longevity, IQ, eye color
• Leading genetics bodies say accuracy and clinical value remain unproven
• Service costs can exceed $50,000 plus IVF expenses

Pulse Analysis

The market for polygenic embryo screening is emerging as a niche within the broader fertility industry. Companies like Herasight in North Carolina, Orchid Health in California, and New York‑based Nucleus Genomics analyze DNA from parental saliva, blood and embryo cells to generate polygenic risk scores. These scores estimate the likelihood of thousands of health outcomes and even non‑medical traits such as height, body‑mass index, longevity and intelligence. By packaging the data alongside traditional IVF cycles, providers charge premium fees—often $50,000 or more—targeting risk‑averse parents who want to minimize the chance of inherited diseases and, increasingly, to influence desirable traits.

Scientific and ethical scrutiny, however, remains intense. The American College of Medical Genetics and Genomics and the American Association of Reproductive Medicine have warned that polygenic risk scores for embryos lack sufficient validation, especially for complex traits like IQ or physical appearance. Environmental factors and lifestyle play a major role, and the predictive power of current models is limited. Bioethicists caution that the technology could create unrealistic expectations, exacerbate socioeconomic disparities, and open a pathway to a "designer baby" market that challenges long‑standing norms about reproductive autonomy and equity.

If consumer demand persists, the sector could experience rapid growth, prompting regulators to develop clearer guidelines. Investors are watching closely, as the convergence of genomics, AI‑driven analytics and assisted‑reproductive technology promises new revenue streams. Yet sustainable adoption will likely hinge on robust clinical evidence, transparent risk communication, and policies that balance innovation with societal concerns. Stakeholders—from fertility clinics to policymakers—must navigate a delicate balance between offering hopeful options to families and safeguarding against premature commercialization of unproven genetic predictions.